Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology
+$0.03 today
- Market cap
- $51.08M
- Beta
- 0.28
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.22
Volume 1.26M
Average 3.36M
MREO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Mereo BioPharma Group plcNASDAQ: MREO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $4.02M fell 44.7% year over year, behind the -28.1% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 4.2% from the prior quarter. Over 3 fiscal years it compounded at -0.2% a year.
Context
- Selling, general & admin amounted to 4601.6% of revenue in FY2025.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $17.85M (-22.4%) for the fiscal year ending Dec 2026, a slowdown from the -13.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.02M-4.2% QoQ
- Last fiscal yearDec 2025
- $23.01M-13.0% YoY
- LTMMar 2026
- $19.76M-28.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 23.01M USD
- Year-over-year change
- -13.0%
- 4-year CAGR
- +1.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.01M | -13.0% |
| FY2024 | 2024-12-31 | 26.43M | +43.5% |
| FY2023 | 2023-12-31 | 18.42M | -20.5% |
| FY2022 | 2022-12-31 | 23.18M | +7.8% |
| FY2021 | 2021-12-31 | 21.5M | — |
Selling, General & Admin vs competitors
How MREO compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -28.1% is the lowest of 10, against a peer median of +18.2%.
- Selling, general & admin amounts to 3951.0% of revenue for MREO, versus a peer median of 239.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.14T USD | +9732467.6% | -14.5% | — | |
| LTM Mar 2026 | $37.43M USD | +18.7% | +65.2% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $35.46M USD | -13.0% | +55.9% | — |
| LTM Mar 2026 | $26.76M USD | +58.7% | +29.7% | — | |
| LTM Mar 2026 | $23.59M USD | — | +2.2% | 2560.2% | |
| LTM Mar 2026 | $20.1M USD | +39.9% | +8.1% | — | |
| LTM Mar 2026 | $19.76M USD | -28.1% | -0.2% | 3951.0% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $17.4M USD | +18.2% | +41.6% | — |
| LTM Mar 2026 | €14.33M EUR | +6.6% | -8.9% | 106.6% | |
| LTM Mar 2026 | CHF 11.38M CHF | +4.4% | +6.7% | 307.5% | |
| FY2025 | A$8.64M AUD | -2.4% | +6.2% | 171.4% | |
| Peer median (excluding MREO) | — | +18.2% | +7.4% | 239.4% | |
Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 49.21M | 0 | 10M | 0 | 500K |
| Cost of Revenue | 24.17M | (257.44K) | 2.57M | 1.09M | 133K |
| Gross Profit | 25.04M | 257.44K | 7.43M | (1.09M) | 367K |
| Gross Margin | 50.9% | — | 74.3% | — | 73.4% |
| Research & Development | 31.8M | 30.75M | 17.42M | 20.93M | 17.77M |
| Selling, General & Admin | 21.5M | 23.18M | 18.42M | 26.43M | 23.01M |
| Operating Expenses | 53.3M | 53.92M | 35.84M | 47.36M | 38.62M |
| Depreciation & Amortization | 866.47K | 895.5K | 1.06M | 1.09M | 1.15M |
| EBITDA | 25.49M | (39.98M) | (26.06M) | (40.8M) | (40.47M) |
| EBITDA Margin | 51.8% | — | -260.6% | — | -8094.8% |
| Operating Income | (28.26M) | (53.67M) | (28.42M) | (47.36M) | (38.26M) |
| Operating Margin | -57.4% | — | -284.2% | — | -7651.4% |
| Interest Income | 1.38K | 696K | 2.13M | 3.04M | 2.17M |
| Interest Expense | 5.22M | 3.36M | 2.88M | 1.37M | 255K |
| Other Income / Expenses | 47.48M | 9.21M | (1.58M) | 4.11M | (3.62M) |
| Income Before Tax | 19.22M | (44.46M) | (30M) | (43.25M) | (41.88M) |
| Pre-Tax Margin | 39.1% | — | -300.0% | — | -8375.6% |
| Income Tax Expense | 2.05M | (2.34M) | (532K) | 0 | 0 |
| Net Income | 17.17M | (42.12M) | (29.47M) | (43.25M) | (41.88M) |
| Net Margin | 34.9% | — | -294.7% | — | -8375.6% |
| EPS (Basic) | 749.65 | (1,750.35) | (1,100.22) | (0.29) | (0.26) |
| EPS (Diluted) | 749.65 | (1,750.35) | (1,100.22) | (0.29) | (0.26) |
| Weighted Avg Shares | 116.73M | 120.64M | 131.89M | 147.92M | 159.42M |
| Weighted Avg Shares (Diluted) | 116.73M | 120.64M | 131.89M | 147.92M | 159.42M |
Mereo BioPharma Group plc
NASDAQ:MREO
Intrinsic Alpha fair value
Locked
Current Price
$0.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.